News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
18,255 Results
Type
Article (311)
Press Release (17944)
Section
Business (9653)
Career Advice (11)
Deals (1265)
Drug Delivery (1)
Drug Development (1518)
Employer Resources (1)
FDA (271)
Job Trends (476)
News (11930)
Policy (506)
Tag
Academia (22)
Accelerated approval (1)
Adcomms (2)
Allergies (4)
Alliances (330)
ALS (5)
Alzheimer's disease (25)
Antibody-drug conjugate (ADC) (11)
Approvals (303)
Artificial intelligence (9)
Autoimmune disease (3)
Automation (1)
Bankruptcy (2)
Best Places to Work (475)
BIOSECURE Act (1)
Biosimilars (2)
Biotechnology (1)
Bladder cancer (17)
Breast cancer (27)
Cancer (197)
Cardiovascular disease (13)
Career advice (7)
CAR-T (4)
Cell therapy (10)
Cervical cancer (3)
Clinical research (1546)
Collaboration (18)
Compensation (42)
COVID-19 (18)
C-suite (2)
Cystic fibrosis (3)
Data (310)
Depression (7)
Diabetes (8)
Diagnostics (229)
Digital health (2)
Drug discovery (2)
Drug pricing (3)
Duchenne muscular dystrophy (6)
Earnings (10143)
Editorial (1)
Events (1996)
Executive appointments (3)
FDA (455)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (12)
Gene editing (2)
Gene therapy (7)
GLP-1 (17)
Government (57)
Guidances (117)
Healthcare (574)
HIV (2)
IgA nephropathy (2)
Immunology and inflammation (13)
Indications (5)
Infectious disease (24)
Inflammatory bowel disease (4)
Influenza (2)
Intellectual property (3)
IPO (1123)
Job creations (29)
Job search strategy (7)
Kidney cancer (2)
Labor market (5)
Layoffs (13)
Legal (65)
Lung cancer (32)
Lymphoma (28)
Machine learning (1)
Manufacturing (13)
MASH (8)
Medical device (511)
Medtech (516)
Mergers & acquisitions (174)
Metabolic disorders (33)
Multiple sclerosis (9)
NASH (2)
Neurodegenerative disease (4)
Neuropsychiatric disorders (4)
Neuroscience (70)
NextGen: Class of 2026 (87)
Non-profit (42)
Obesity (13)
Ovarian cancer (6)
Pain (4)
Pancreatic cancer (8)
Parkinson's disease (7)
Patents (7)
Patient recruitment (5)
Peanut (1)
People (274)
Pharmacy benefit managers (1)
Phase 1 (380)
Phase 2 (556)
Phase 3 (725)
Pipeline (524)
Policy (2)
Postmarket research (56)
Preclinical (129)
Prostate cancer (12)
Psychedelics (1)
Radiopharmaceuticals (4)
Rare diseases (14)
Real estate (30)
Regulatory (479)
Reports (5)
Research institute (18)
Rett syndrome (1)
RSV (1)
Schizophrenia (6)
Series A (1)
Series B (1)
Special edition (5)
Spinal muscular atrophy (6)
Startups (20)
Stomach cancer (1)
Tariffs (2)
Vaccines (9)
Venture capital (1)
Weight loss (6)
Women's health (3)
Date
Today (3)
Last 7 days (30)
Last 30 days (67)
Last 365 days (1454)
2026 (84)
2025 (1521)
2024 (1513)
2023 (1707)
2022 (2009)
2021 (1923)
2020 (1618)
2019 (1113)
2018 (827)
2017 (599)
2016 (430)
2015 (747)
2014 (441)
2013 (286)
2012 (298)
2011 (339)
2010 (386)
Location
Africa (9)
Alabama (4)
Arizona (7)
Asia (925)
Australia (76)
California (470)
Canada (91)
China (20)
Colorado (31)
Connecticut (24)
Delaware (14)
Europe (2423)
Florida (85)
Georgia (23)
Idaho (2)
Illinois (34)
India (7)
Indiana (17)
Iowa (3)
Japan (14)
Kansas (5)
Kentucky (1)
Louisiana (6)
Maine (7)
Maryland (57)
Massachusetts (303)
Michigan (17)
Minnesota (35)
Mississippi (2)
Missouri (2)
Montana (1)
Nebraska (2)
Nevada (3)
New Hampshire (7)
New Jersey (174)
New York (119)
North Carolina (66)
Northern California (260)
Ohio (9)
Pennsylvania (116)
Rhode Island (1)
South America (26)
Southern California (178)
Tennessee (5)
Texas (56)
United States (1732)
Utah (20)
Virginia (2)
Washington State (40)
Wisconsin (5)
18,255 Results for "172".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5M
November 17, 2025
·
14 min read
Press Releases
Cancer Biopsy Market Forecasted to Surpass USD 172.29 Billion By 2034
February 26, 2025
·
1 min read
Press Releases
Angelman Syndrome Market Size to Reach USD 172.8 Million by 2035, Impelled by Advancements in Genetic and Molecular Research
January 23, 2025
·
10 min read
Press Releases
Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases
October 16, 2024
·
6 min read
Press Releases
Cancer Biopsy Market to Skyrocket to USD 172.29 Billion by 2034, with a Robust 18.8% CAGR
August 7, 2024
·
12 min read
Biotech Beach
Janux’s Stock Skyrockets 172% on Positive Results for Two Candidates in Phase I Trials
Janux Therapeutics on Monday announced positive updated clinical data for both of its clinical programs in prostate cancer advanced or metastatic solid tumors.
February 27, 2024
·
2 min read
·
Tyler Patchen
Pharm Country
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Tourmaline Bio, Inc. announced the closing of its previously-announced underwritten public offering of 5,307,691 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 692,307 additional shares, at a public offering price of $32.50 per share.
January 29, 2024
·
5 min read
Biotech Bay
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
Iovance Biotherapeutics, Inc. announced the closing of an underwritten public offering of 23,000,000 shares of its common stock at a public offering price of $7.50 per share.
July 13, 2023
·
5 min read
Pharm Country
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
Outlook Therapeutics, Inc. today announced that it has received written agreement from the FDA under an SPA for the NORSE EIGHT clinical trial protocol evaluating ONS-5010 in neovascular age-related macular degeneration (AMD) subjects.
January 23, 2024
·
11 min read
Exosome Research Market Will Grow at a CAGR of 16.26% 2024-2031
Global Exosome Research Market is valued at US$ 172.30 Mn in 2023, and it is expected to reach US$ 570.70 Mn by 2031, with a CAGR of 16.26% during the forecast period of 2024-2031.
April 22, 2024
·
4 min read
1 of 1,826
Next
